drugset
drugset / Trial / NCT04508075

Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine

NCT04508075 ↗

Phase 3 Completed 1620 enrolled PT Bio Farma Faculty of Medicine Universitas Padjadjaran · collabNational Institute of Health Research and Development, Ministry of Health Republic of Indonesia · collabSinovac Life Sciences Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation

Timeline

Start
2020-08-10
Primary completion
2021-01-09
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SARS-Cov-2 Vaccine Inactivated Vaccine — Intramuscular

Indications

COVID-19